Personalized cancer therapy using a patient-derived tumor tissue xenograft model: a translational field worthy of exploring further?

Personalized Medicine
Ketao JinLisong Teng

Abstract

It has long been observed that interpatient variability in response to anticancer drugs is associated with different outcomes. Oncologists continually hold the desire of matching the right therapeutic regimen with the right cancer patient, which is termed 'personalized cancer therapy'. Rapid advances in genetics, genomics and related technologies are promising a new era of personalized cancer therapy based on individual molecular biomarkers. However, these molecular predictors of tumor response are far from perfect. Because of the inherent limitations in the current approaches for anticancer drugs response prediction, the need for new techniques to predict tumor response to therapy is urgent. Using a patient-derived human tumor tissue (PDTT) xenograft model to predict tumor response to therapy might be an ideal candidate method to choose. This article provides an overview of the achievements and limitations of genetic, genomic and proteomic molecular markers for personalized cancer therapy, and further discusses the potentials of using a PDTT xenograft model as a candidate strategy for personalized cancer therapy.

References

Jan 1, 1996·Breast Cancer Research and Treatment·R Clarke
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Apr 23, 2002·Pharmacogenomics·Howard L McLeod, Chokkalingam Siva
Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·André B P Van KuilenburgAlbert H Van Gennip
Aug 5, 2003·The Oncologist·Jeffrey S RossKenneth J Bloom
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian J Druker
Jan 2, 2004·European Journal of Cell Biology·Léon C L T van KempenLisa M Coussens
May 4, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L R Kelland
Nov 19, 2004·Nature·Neil A BhowmickHarold L Moses
Nov 24, 2004·Trends in Pharmacological Sciences·William P Petros, William E Evans
Jan 6, 2005·Journal of the National Cancer Institute·Yan JinDavid A Flockhart
Mar 3, 2005·Genome Research·Chang Gue SonJaved Khan
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Pao, Vincent A Miller
Mar 24, 2005·JAMA : the Journal of the American Medical Association·Martin StanullaMatthias Schwab
Jul 15, 2005·The New England Journal of Medicine·Daniela S Krause, Richard A Van Etten
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James D BrentonCarlos Caldas
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daphne W BellDaniel A Haber
Oct 26, 2005·Human Molecular Genetics·Wolfgang Sadée, Zunyan Dai
Nov 4, 2005·Investigational New Drugs·Sharon Marsh
Dec 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew P GoetzJames N Ingle
Mar 23, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark J Ratain
Apr 6, 2006·Cancer Research·Edward A Sausville, Angelika M Burger
Apr 13, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew P GoetzFergus J Couch
Jun 9, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M V CéspedesR Mangues
Jul 4, 2006·Trends in Pharmacological Sciences·Michael L MaitlandMark J Ratain
Jul 22, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hung HuynhEvelyn Tran
Aug 11, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Belen Rubio-ViqueiraManuel Hidalgo
Oct 24, 2006·Nature Medicine·Anil PottiJoseph R Nevins
Oct 27, 2006·Pediatric Blood & Cancer·Peter J HoughtonMalcolm A Smith
Mar 14, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jane L Yen, Howard L McLeod
Apr 26, 2007·Pediatric Blood & Cancer·John M MarisMalcolm A Smith
Jul 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elisabetta MarangoniMarie-France Poupon
Oct 11, 2007·Pharmacogenomics·Christine M Hartford, M Eileen Dolan
Nov 15, 2007·Journal of the National Cancer Institute·Lara LusaMarco A Pierotti
Nov 24, 2007·Pharmacogenomics·Marie-Christine Etienne-GrimaldiGérard Milano

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
xenografts
xenografting
biopsy

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Related Papers

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
W WuJ J Kavanagh
Drug Metabolism and Personalized Therapy
Ana E Rodríguez-VicenteMiquel Taron
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
Nora M Gerhards, Sven Rottenberg
© 2022 Meta ULC. All rights reserved